Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery

Purpose: To study the role of daunorubicin in inhibiting pro­liferative vitreoretinopathy after retinal detachment surgery. Method: Thirty eyes of 30 patients with a primary rhegmato­genous retinal detachment and proliferative vitreoretin­opathy of stage D1 or more advanced were included in the stud...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & experimental ophthalmology 2002-10, Vol.30 (5), p.348-351
Hauptverfasser: Kumar, Atul, Nainiwal, Sanjeev, Choudhary, Indranil, Tewari, Hem K, Verma, Lalit K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 351
container_issue 5
container_start_page 348
container_title Clinical & experimental ophthalmology
container_volume 30
creator Kumar, Atul
Nainiwal, Sanjeev
Choudhary, Indranil
Tewari, Hem K
Verma, Lalit K
description Purpose: To study the role of daunorubicin in inhibiting pro­liferative vitreoretinopathy after retinal detachment surgery. Method: Thirty eyes of 30 patients with a primary rhegmato­genous retinal detachment and proliferative vitreoretin­opathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of dauno­rubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery. Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group. Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.
doi_str_mv 10.1046/j.1442-9071.2002.00554.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72065432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72065432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</originalsourceid><addsrcrecordid>eNqNkFtP9CAQhonReP4LhivvWoFCS5Pvxmx018RoYjxcEtoOLvt12xWo7v572UP01gzJTJj3HZgHIUxJSgnPr2Yp5ZwlJSloyghhKSFC8HS5h45_Gvu7OueEH6ET72ckqliWH6IjyhjNqCiPUf3Ut4B7gxs9dL0bKlvbDm_O1FY22O4dL1zfWgNOB_sJ-NMGB72D2OoXOkxXWJsADm9udIsbCLqezqEL2A_uHdzqDB0Y3Xo43-VT9HJ78zyaJPeP47vR9X1Sc8J4kkvNGslEWUEpc6CaAS0EI0abKqNQUs1jCFmRksVoZB73y4yQXFeyliY7RZfbufHDHwP4oObW19C2uoN-8KpgJBc8Y1Eot8La9d47MGrh7Fy7laJErQGrmVqzU2uOag1YbQCrZbRe7N4Yqjk0v8Yd0Sj4txV82RZWfx6sRjePsYj2ZGu3PsDyx67df5UXWSHU28NYsdfJRJIxU8_ZNwb5mh0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72065432</pqid></control><display><type>article</type><title>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Kumar, Atul ; Nainiwal, Sanjeev ; Choudhary, Indranil ; Tewari, Hem K ; Verma, Lalit K</creator><creatorcontrib>Kumar, Atul ; Nainiwal, Sanjeev ; Choudhary, Indranil ; Tewari, Hem K ; Verma, Lalit K</creatorcontrib><description>Purpose: To study the role of daunorubicin in inhibiting pro­liferative vitreoretinopathy after retinal detachment surgery. Method: Thirty eyes of 30 patients with a primary rhegmato­genous retinal detachment and proliferative vitreoretin­opathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of dauno­rubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery. Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group. Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.</description><identifier>ISSN: 1442-6404</identifier><identifier>EISSN: 1442-9071</identifier><identifier>DOI: 10.1046/j.1442-9071.2002.00554.x</identifier><identifier>PMID: 12213159</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Pty</publisher><subject>Antibiotics, Antineoplastic - therapeutic use ; daunorubicin ; Daunorubicin - therapeutic use ; Female ; Humans ; Injections ; intravitreal ; Male ; Middle Aged ; proliferative vitreo­retinopathy ; retinal detachment ; Retinal Detachment - complications ; Retinal Detachment - surgery ; retinal pigment epithelium ; Scleral Buckling ; Visual Acuity ; Vitrectomy ; Vitreoretinopathy, Proliferative - etiology ; Vitreoretinopathy, Proliferative - prevention &amp; control ; Vitreous Body</subject><ispartof>Clinical &amp; experimental ophthalmology, 2002-10, Vol.30 (5), p.348-351</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</citedby><cites>FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1442-9071.2002.00554.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1442-9071.2002.00554.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12213159$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Atul</creatorcontrib><creatorcontrib>Nainiwal, Sanjeev</creatorcontrib><creatorcontrib>Choudhary, Indranil</creatorcontrib><creatorcontrib>Tewari, Hem K</creatorcontrib><creatorcontrib>Verma, Lalit K</creatorcontrib><title>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</title><title>Clinical &amp; experimental ophthalmology</title><addtitle>Clin Exp Ophthalmol</addtitle><description>Purpose: To study the role of daunorubicin in inhibiting pro­liferative vitreoretinopathy after retinal detachment surgery. Method: Thirty eyes of 30 patients with a primary rhegmato­genous retinal detachment and proliferative vitreoretin­opathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of dauno­rubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery. Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group. Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.</description><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>daunorubicin</subject><subject>Daunorubicin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Injections</subject><subject>intravitreal</subject><subject>Male</subject><subject>Middle Aged</subject><subject>proliferative vitreo­retinopathy</subject><subject>retinal detachment</subject><subject>Retinal Detachment - complications</subject><subject>Retinal Detachment - surgery</subject><subject>retinal pigment epithelium</subject><subject>Scleral Buckling</subject><subject>Visual Acuity</subject><subject>Vitrectomy</subject><subject>Vitreoretinopathy, Proliferative - etiology</subject><subject>Vitreoretinopathy, Proliferative - prevention &amp; control</subject><subject>Vitreous Body</subject><issn>1442-6404</issn><issn>1442-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkFtP9CAQhonReP4LhivvWoFCS5Pvxmx018RoYjxcEtoOLvt12xWo7v572UP01gzJTJj3HZgHIUxJSgnPr2Yp5ZwlJSloyghhKSFC8HS5h45_Gvu7OueEH6ET72ckqliWH6IjyhjNqCiPUf3Ut4B7gxs9dL0bKlvbDm_O1FY22O4dL1zfWgNOB_sJ-NMGB72D2OoXOkxXWJsADm9udIsbCLqezqEL2A_uHdzqDB0Y3Xo43-VT9HJ78zyaJPeP47vR9X1Sc8J4kkvNGslEWUEpc6CaAS0EI0abKqNQUs1jCFmRksVoZB73y4yQXFeyliY7RZfbufHDHwP4oObW19C2uoN-8KpgJBc8Y1Eot8La9d47MGrh7Fy7laJErQGrmVqzU2uOag1YbQCrZbRe7N4Yqjk0v8Yd0Sj4txV82RZWfx6sRjePsYj2ZGu3PsDyx67df5UXWSHU28NYsdfJRJIxU8_ZNwb5mh0</recordid><startdate>200210</startdate><enddate>200210</enddate><creator>Kumar, Atul</creator><creator>Nainiwal, Sanjeev</creator><creator>Choudhary, Indranil</creator><creator>Tewari, Hem K</creator><creator>Verma, Lalit K</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200210</creationdate><title>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</title><author>Kumar, Atul ; Nainiwal, Sanjeev ; Choudhary, Indranil ; Tewari, Hem K ; Verma, Lalit K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4024-68a2d8259be986e1a2e17520fafb31e91a4a4a58b092929d861443f584ab8c8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>daunorubicin</topic><topic>Daunorubicin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Injections</topic><topic>intravitreal</topic><topic>Male</topic><topic>Middle Aged</topic><topic>proliferative vitreo­retinopathy</topic><topic>retinal detachment</topic><topic>Retinal Detachment - complications</topic><topic>Retinal Detachment - surgery</topic><topic>retinal pigment epithelium</topic><topic>Scleral Buckling</topic><topic>Visual Acuity</topic><topic>Vitrectomy</topic><topic>Vitreoretinopathy, Proliferative - etiology</topic><topic>Vitreoretinopathy, Proliferative - prevention &amp; control</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Atul</creatorcontrib><creatorcontrib>Nainiwal, Sanjeev</creatorcontrib><creatorcontrib>Choudhary, Indranil</creatorcontrib><creatorcontrib>Tewari, Hem K</creatorcontrib><creatorcontrib>Verma, Lalit K</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical &amp; experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Atul</au><au>Nainiwal, Sanjeev</au><au>Choudhary, Indranil</au><au>Tewari, Hem K</au><au>Verma, Lalit K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery</atitle><jtitle>Clinical &amp; experimental ophthalmology</jtitle><addtitle>Clin Exp Ophthalmol</addtitle><date>2002-10</date><risdate>2002</risdate><volume>30</volume><issue>5</issue><spage>348</spage><epage>351</epage><pages>348-351</pages><issn>1442-6404</issn><eissn>1442-9071</eissn><abstract>Purpose: To study the role of daunorubicin in inhibiting pro­liferative vitreoretinopathy after retinal detachment surgery. Method: Thirty eyes of 30 patients with a primary rhegmato­genous retinal detachment and proliferative vitreoretin­opathy of stage D1 or more advanced were included in the study. The eyes were randomly assigned to either the experimental or the control group. The eyes in the experimental group received an intravitreal injection of dauno­rubicin (5 µg) before conclusion of the vitrectomy. The main outcome measures evaluated were: retinal attachment, vitreous activity and visual acuity at 3 months after surgery. Results: Complete retinal attachment was achieved in 13 eyes (86.6%) in the daunorubicin group and 10 eyes (66.6%) in the control group, at 3 months. Nine patients (60%) in the daunorubicin group and five patients (33.3%) in the control group had a best‐corrected visual acuity of ≥3/60 at 3 months of follow up. There was a statistically significant reduction in vitreous reaction at all times during the postoperative period in the daunorubicin group. Conclusion: Daunorubicin may be a useful drug in inhibiting proliferative vitreoretinopathy after surgery for primary rhegmatogenous retinal detachment.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Pty</pub><pmid>12213159</pmid><doi>10.1046/j.1442-9071.2002.00554.x</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1442-6404
ispartof Clinical & experimental ophthalmology, 2002-10, Vol.30 (5), p.348-351
issn 1442-6404
1442-9071
language eng
recordid cdi_proquest_miscellaneous_72065432
source MEDLINE; Wiley Online Library All Journals
subjects Antibiotics, Antineoplastic - therapeutic use
daunorubicin
Daunorubicin - therapeutic use
Female
Humans
Injections
intravitreal
Male
Middle Aged
proliferative vitreo­retinopathy
retinal detachment
Retinal Detachment - complications
Retinal Detachment - surgery
retinal pigment epithelium
Scleral Buckling
Visual Acuity
Vitrectomy
Vitreoretinopathy, Proliferative - etiology
Vitreoretinopathy, Proliferative - prevention & control
Vitreous Body
title Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A44%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20daunorubicin%20in%20inhibiting%20proliferative%20vitreoretinopathy%20after%20retinal%20detachment%20surgery&rft.jtitle=Clinical%20&%20experimental%20ophthalmology&rft.au=Kumar,%20Atul&rft.date=2002-10&rft.volume=30&rft.issue=5&rft.spage=348&rft.epage=351&rft.pages=348-351&rft.issn=1442-6404&rft.eissn=1442-9071&rft_id=info:doi/10.1046/j.1442-9071.2002.00554.x&rft_dat=%3Cproquest_cross%3E72065432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72065432&rft_id=info:pmid/12213159&rfr_iscdi=true